Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Sponsor: University Of Nigeria Teaching Hospital
Summary
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
Official title: Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People
Key Details
Gender
All
Age Range
20 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
220
Start Date
2025-07-23
Completion Date
2027-09-30
Last Updated
2025-12-22
Healthy Volunteers
No
Interventions
Metformin
Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily
Placebo
Starch-based, identical looking placebo
Locations (2)
Pathology Facility
Enugu, Enugu State, Nigeria
University of Nigeria Teaching Hospital
Enugu, Enugu State, Nigeria